The incidence of cutaneous squamous cell carcinoma is on the rise worldwide, a trend largely attributed to aging populations and cumulative exposure to solar ultraviolet (UV) radiation, which remains the primary environmental risk factor for the disease. While the vast majority of cSCC cases are successfully managed through the surgical excision of the primary tumor, the disease carries a hidden danger. Approximately 3% to 5% of these primary tumors will eventually metastasize, spreading to lymph nodes or distant organs. Once the cancer reaches this stage, the prognosis for the patient drops significantly, and the available treatment options become increasingly limited and less effective. Despite its reputation as a generally curable condition, cSCC is estimated to account for nearly 25% of all annual deaths related to skin cancer, highlighting a critical gap in early detection and specialized care for high-risk patients.
The search for reliable molecular markers has become a priority for oncologists specializing in dermatology. Lead investigator Veli-Matti Kähäri, MD, PhD, who works within the Department of Dermatology and the FICAN West Cancer Research Laboratory at the University of Turku, noted the current limitations in the field. He explained that there are presently no established molecular markers used in routine clinical practice that can accurately predict which primary cSCC tumors are likely to metastasize. This leaves doctors relying on tumor size, depth, and location to guess at the risk, which is often insufficient for catching the most aggressive cases before they spread. Dr. Kähäri emphasized that there is an urgent and ongoing need for predictive biomarkers that can clarify a patient’s prognosis and serve as targets for the development of new, more effective therapies for metastatic disease.
To address this need, the research team turned their attention to the complement system, an ancient and essential component of the human innate immune system. Traditionally, the complement system is understood as a defense mechanism—a series of proteins that work together to identify and destroy invading pathogens or clear out damaged cells. It is often described as a tumor-suppressing cytolytic mechanism. However, recent scientific inquiries across various types of cancer have begun to reveal a darker side to this immune response. In certain contexts, the complement system can be "hijacked" by a tumor, contributing to cancer progression and metastasis by fostering chronic inflammation or inducing a state of immunosuppression that allows the tumor to hide from the body’s natural defenses.
The Finnish researchers specifically focused on the interaction between a signaling molecule called C5a and its corresponding protein receptor, C5aR1. C5a is a potent inflammatory mediator, and its receptor, C5aR1, is typically found on the surface of various immune cells. In the context of the current study, the investigators sought to understand how this relationship functioned within the specific environment of cutaneous squamous cell carcinoma. They hypothesized that the activation of C5aR1 might be a key driver in the transition of a localized skin tumor into an invasive, life-threatening malignancy.
The methodology of the study was comprehensive, involving a multi-layered approach to validate their findings. The researchers utilized in vitro 3D spheroid co-cultures, which allowed them to observe the interaction between cSCC cells and skin fibroblasts in a laboratory setting that mimics the actual structure of human tissue. They also employed human cSCC xenograft tumors grown in SCID (Severe Combined Immunodeficiency) mice, providing a living model to observe how these tumors behave in a complex biological system. Finally, the team analyzed a massive panel of patient-derived tumor samples. This collection included samples of non-metastatic cSCC, primary tumors that had eventually metastasized, and the metastases themselves. By comparing these different stages of the disease, the researchers could pinpoint exactly when and where C5aR1 was most active.
During their investigations, the team noted that when the signaling molecule C5a binds to the C5aR1 receptor on the surface of a cell, it triggers a cascade of internal signaling pathways. These pathways effectively "reprogram" the cell’s behavior, encouraging it to become more mobile and invasive. First author Lauri Heiskanen, MD, also from the Department of Dermatology and the FICAN West Cancer Research Laboratory, provided further detail on the role of the tumor microenvironment. He explained that the study observed how fibroblasts—cells that normally provide structural support to the skin—actually induced the expression of C5aR1 within the cSCC cells themselves.
This interaction suggests that the tumor does not act alone; it recruits surrounding healthy cells to aid in its growth. When the researchers exposed these cells to recombinant C5a in a controlled environment, they witnessed a marked increase in the invasiveness of the cSCC cells. The clinical data from patient samples further reinforced these laboratory observations. In patients, high levels of C5aR1 expression were found not only in the tumor cells themselves but also in the surrounding stromal fibroblasts. Crucially, this elevated expression was consistently linked to a higher risk of metastasis and a lower rate of overall survival.
One of the more surprising elements of the study was the significant role played by the fibroblasts in the tumor microenvironment. While researchers have long known that the area surrounding a tumor can influence its growth, the discovery that these specific cells were responsible for turning on the C5aR1 "switch" in cancer cells was unexpected. Furthermore, the fact that the presence of C5aR1 within the fibroblasts themselves could serve as a predictor for a patient’s death or the spread of their cancer added a new layer of complexity to the understanding of the disease. The researchers had not initially anticipated that the correlation between C5aR1 expression and patient outcomes would be so strong and consistent across such a large and diverse clinical sample set.
Co-investigators Pilvi Riihilä, MD, PhD, and Liisa Nissinen, PhD, both of whom contributed significantly to the research at the University of Turku, highlighted the broader implications of these results. They pointed out that the most compelling aspect of the findings is the demonstration of how the tumor microenvironment—specifically the interplay between the cancer cells and the stromal fibroblasts—dictates the progression of cSCC through the C5aR1 pathway. This reinforces a growing consensus in modern oncology that cancer cannot be understood or treated as an isolated group of malignant cells, but rather as a complex ecosystem where the surrounding tissue plays a vital, and sometimes treacherous, role in the development of the disease.
The identification of C5aR1 as a biomarker offers a two-fold benefit for the future of skin cancer treatment. First, it provides a potential diagnostic tool. If a primary cSCC tumor shows high levels of C5aR1 expression during a routine biopsy, doctors could identify that patient as being at high risk for metastasis. This would allow for more aggressive initial treatment, closer monitoring, and potentially life-saving early intervention. Second, C5aR1 represents a promising target for new pharmacological therapies. If drugs can be developed to block the C5aR1 receptor or inhibit the signaling pathways it activates, it might be possible to prevent the cancer from becoming invasive, effectively "locking" the tumor in place and making it much easier to treat surgically.
As the global medical community continues to grapple with the rising rates of skin cancer, the work coming out of the University of Turku and Turku University Hospital provides a vital piece of the puzzle. By moving beyond simple observation and into the molecular mechanics of how skin cancer spreads, these researchers have opened a new door for prognostic testing and precision medicine. The study concludes that C5aR1 is not just a passive marker of a dangerous tumor, but a functional participant in the tumor’s ability to spread, making it one of the most significant discoveries in the study of cutaneous squamous cell carcinoma in recent years. This work lays the groundwork for future clinical trials that may one day integrate C5aR1 testing into standard dermatological care, offering hope for better survival rates and more personalized treatment plans for patients facing this aggressive disease.
